- Home
- DFLI vs TOVX Comparison
DFLI vs TOVX Comparison
Compare DFLI & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DFLI | TOVX |
|---|---|---|
| Founded | 2020 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.6M | 11.1M |
| IPO Year | 2021 | 2012 |
Fundamental Metrics
Financial Performance| Metric | DFLI | TOVX |
|---|---|---|
| Price | $0.46 | $0.22 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $2.50 |
| AVG Volume (30 Days) | 321.4K | ★ 363.9K |
| Earning Date | 11-13-2026 | 08-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 89.07 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $58,630,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $61.43 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 15.77 | N/A |
| 52 Week Low | $0.41 | $0.16 |
| 52 Week High | $5.15 | $0.86 |
Technical Indicators
Market Signals| Indicator | DFLI | TOVX |
|---|---|---|
| Relative Strength Index (RSI) | 15.21 | 44.85 |
| Support Level | N/A | $0.17 |
| Resistance Level | $2.24 | $0.26 |
| Average True Range (ATR) | 0.08 | 0.01 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 9.62 | 27.17 |
Price Performance
Historical ComparisonAbout DFLI Dragonfly Energy Holdings Corp. (NV)
Dragonfly Energy Holdings Corp is engaged in the design, assembly, and sale of lithium-ion batteries, mainly lithium iron phosphate (LFP) batteries, for applications in recreational vehicles, marine, industrial, and other markets. The company operates through two segments: direct-to-consumer (DTC), which sells Battle Born branded batteries, and OEM, which supplies Dragonfly branded batteries to original equipment manufacturers.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.